

or to the offices of the Board of Governors. Comments must be received not later than February 22, 1994.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Danny Gerald Snow*, Manassas, Virginia; to acquire an additional 3.27 percent of the voting shares of Security Bank Corporation, Manassas, Virginia, for a total of 10.67 percent.

B. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. *Preston Turner Bostwick*, Arlington, Georgia; to retain 60.3 percent of the voting shares of B.H.C., Inc., Arlington, Georgia, and thereby indirectly acquire Bostwick Banking Co., Arlington, Georgia.

C. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *James L. Blin*, Osprey, Florida; *Bywater Properties*, Iowa City, Iowa; *Willis Crees*, Waterloo, Iowa; *Collin Fritz*, Peoria, Arizona; *Vernon Hoffman*, Independence, Iowa; *William Kuehn*, Sumner, Iowa; *Gary Short* and *Harriet Short*, both of Independence, Iowa; to acquire an additional 68.35 percent of the voting shares of Independence Bancshares, Inc., Independence, Iowa, for a total of 81.91 percent, and thereby indirectly acquire Security State Bank, Independence, Iowa, and First State Bancorporation, Independence, Iowa, and thereby indirectly acquire Northeast Security Bank, Sumner, Iowa.

2. *Van A. Dukeman*, David J. Downey, George T. Shapland and Gregory B. Lykins, all of Champaign, Illinois; to acquire, as a group, 33.19 percent of the voting shares of Bank Illinois Financial Co., Champaign, Illinois, and thereby indirectly acquire Bank of Illinois in Champaign, Illinois.

D. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Albert Furman*, Glenview, Illinois; to acquire 45.4 percent; *Robert Cook*, Union Grove, Wisconsin, to acquire 7.6 percent; *Robert Durham*, Austin, Texas, to acquire 7.6 percent; *Howard Marvin*, Palm Desert, California, to acquire 7.6 percent; and *Robert Wunsch*, Austin, Texas, to acquire 7.6 percent of the voting shares of Hutto State Bank, Hutto, Texas.

E. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. *Kaharudin Latief*, Jakarta, Indonesia; to acquire 33.3 percent of the voting shares of Bank of San Francisco Company Holding Company, San Francisco, California, and thereby indirectly acquire Bank of San Francisco, San Francisco, California.

Board of Governors of the Federal Reserve System, January 26, 1994.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 94-2306 Filed 2-1-94; 8:45 am]

BILLING CODE 6210-F-M

Southwest Bancshares, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than February 25, 1994.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Southwest Bancshares, Inc.*, Jonesboro, Arkansas; to acquire 100 percent of the voting shares of First Bank of Arkansas, Kensett, Arkansas.

B. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Peoples Bancshares, Inc.*, Clay Center, Kansas; to become a bank holding company by acquiring 100 percent of the voting shares of The Peoples National Bank, Clay Center, Kansas.

Board of Governors of the Federal Reserve System, January 27, 1994.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 94-2323 Filed 2-1-94; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

Low Level Exposure to Chemicals and Neurologic Sensitivity; Meeting

Name: Conference on Low Level Exposure to Chemicals and Neurologic Sensitivity.

Times and Dates: 8 a.m.-5:15 p.m., April 6, 1994. 8 a.m.-4 p.m., April 7, 1994.

Place: The Stouffer Harbor Place Hotel, 202 East Pratt Street, Baltimore, Maryland, 21202, telephone 410/547-1200.

Status: The entire meeting will be open to the public, limited only by space available.

Purpose: To explore clinical observations and basic research information potentially relevant to neurobiologic mechanisms of sensitivity to low level chemical exposures, and to discuss possible tools for advancing the understanding of the neurological effects of low level environmental chemical exposures. The information gained from this meeting will be used by the Agency for Toxic Substances and Disease Registry (ATSDR) to develop testable hypotheses.

Contact Persons for More Information: Patricia Price, M.D., ATSDR, Mailstop E-33, 1600 Clifton Road, NE., Atlanta, Georgia, telephone 404/639-6204; Frank Mitchell, M.D., ATSDR, Mailstop E-28, 1600 Clifton Road, NE., Atlanta, Georgia, telephone 404/639-0700.

Dated: January 27, 1994.

Elvin Hilyer,

Associate Director for Policy Coordination.

[FR Doc. 94-2329 Filed 2-1-94; 8:45 am]

BILLING CODE 4160-70-M

Centers for Disease Control and Prevention

Hospital Infection Control Practices Advisory Committee: Subcommittee on Prevention and Control of Antimicrobial Resistant Microorganisms in Hospitals; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee meeting.

Name: Subcommittee on Prevention and Control of Antimicrobial Resistant Microorganisms in Hospitals.

Time and Date: 9 a.m.-3:30 p.m., February 18, 1994.

Place: CDC, Auditorium A, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will review current knowledge about the epidemiology and laboratory aspects of antimicrobial resistance among nosocomial pathogens and develop an agenda for a workshop later this year to revise and/or develop recommendations to control these pathogens in acute care settings.

Matters to be Discussed: The subcommittee will hold its second meeting to review current knowledge about the epidemiology and laboratory aspects of vancomycin resistance in enterococci and develop a comprehensive strategic plan to detect, prevent, and control resistant enterococci in U.S. hospitals. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Julia S. Garner, R.N., M.N., Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE., Mailstop A-07, Atlanta, Georgia 30333, telephone 404/639-1552.

Dated: January 27, 1994.

Elvin Hilyer,

Associate Director for Policy Coordination,
Centers for Disease Control and Prevention
(CDC).

[FR Doc. 94-2330 Filed 2-1-94; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

[Docket No. 93F-0483]

Rio Linda Chemical Co., Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Rio Linda Chemical Co., Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of chlorine dioxide to disinfect waters contacting fresh meat, fresh poultry, processed meat, and processed poultry.

DATES: Written comments on the petitioner's environmental assessment by March 4, 1994.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Robert L. Martin, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204-0001, 202-254-9519.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))),

notice is given that a food additive petition (FAP 4A4408) has been filed by Rio Linda Chemical Co., Inc., 410 North 10th St., Sacramento, CA 95814. The petition proposes that the food additive regulations be amended to provide for the safe use of chlorine dioxide to disinfect waters contacting fresh meat, fresh poultry, processed meat, and processed poultry.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before March 4, 1994, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m. Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the *Federal Register*. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c).

Dated: January 24, 1994.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 94-2268 Filed 2-1-94; 8:45 am]

BILLING CODE 4160-01-F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in

open public hearings before FDA's advisory committees.

MEETING: The following advisory committee meeting is announced:

Subcommittee Meeting of the Anesthetic and Life Support Drugs Advisory Committee

Date, time, and place. March 1 and 2, 1994, 8 a.m., Potomac Inn, Ballrooms A, B, and C, Three Research Ct., Rockville, MD.

Type of meeting and contact person. Open committee discussion, March 1, 1994, 8 a.m. to 1 p.m.; open public hearing, 1 p.m. to 3 p.m., unless public participation does not last that long; open committee discussion, 3 p.m. to 5 p.m.; open committee discussion, March 2, 1994, 8 a.m. to 1 p.m.; Igor Cerny, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the field of anesthesiology and surgery.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 15, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss how to ensure the safe use of products intended for premedication (including preoperative sedation, conscious sedation, and monitored anesthesia care) in pediatric practice. Recommendations from the meeting will serve as the basis for labeling information that can promote the safe administration of products intended for pediatric premedication.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this

notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a

current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: January 27, 1994.

Jane E. Henney,

Deputy Commissioner for Operation.

[FR Doc. 94-2269 Filed 2-1-94; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Announcement of Application Deadlines for Fiscal Year 1994 for Selected Programs of the Maternal and Child Health Bureau

AGENCY: Health Resources and Services Administration (HRSA), PHS.

ACTION: Advance notice of application deadline dates.

SUMMARY: The Health Resources and Services Administration's Maternal and Child Health Bureau (MCHB) expects to provide funding for new and competing renewal grant projects and cooperative agreements for the following programs during fiscal year 1994. The HRSA is announcing anticipated application deadline, award, funding and project period information for the following categories of: (1) Special Projects of Regional and National Significance (SPRANS) under the MCH Federal Set-Aside Program, funded under section 502(a) of the Social Security Act; (2) HIV Demonstration Program for Children, Adolescents and Families funded under Title IV of the Ryan White C.A.R.E. Act; and (3) Emergency Medical Services for Children Project Grants, funded under section 1910 of the Public Health Service Act.

FOR FURTHER INFORMATION CONTACT:

Potential applicants may contact Chief, Grants Management Branch, Office of Program Support, Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18-12, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-1440 for application information and other programmatic information concerning these programs. Requests should specify the category or categories of activities for which an application is requested.

SUPPLEMENTARY INFORMATION: A Notice of Availability of Funds will be published in the Federal Register for each of these programs, announcing program provisions, priorities, and review criteria. The actual amounts available for awards and their allocation may vary from those in this notice, based on the volume and quality of applications received.

Set forth below is the application information, in table form:

MCH FEDERAL SET-ASIDE GRANT AND COOPERATIVE AGREEMENTS ANTICIPATED DEADLINE, AWARD, FUNDING, AND PROJECT PERIOD INFORMATION, BY CATEGORY [FY 1994]

Funding source category	Application deadline	Estimated number of awards	Estimated amounts available	Project period
Grants in the following areas:				
(1) Research	March 1, 1994-August 1, 1994.	Up to 20	\$2.5 million	Up to 5 years.
(2) Training:				
(2.1) Long term	April 15, 1994	Up to 28	13.4 million	Up to 5 years.
(2.2) Continuing Education	July 1, 1994	Up to 14	750,000	Up to 3 years.
(3) Genetic Disease Testing, Counseling and Information.	April 25, 1994	Up to 18	3 million	3 years.